MarketPulse
N

$NBTX

6 articles found
5 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Nanobiotix

Nanobiotix's NBTXR3 Shows Striking 85.7% Response Rate in Lung Cancer Study

Nanobiotix reports promising Phase 2 data for NBTXR3 in inoperable lung cancer, showing 85.7% response rate versus <5% with standard treatment.
JNJNBTXPhase 2 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Nanobiotix

Nanobiotix's Lung Cancer Drug Shows Striking 85.7% Response Rate in Phase 2 Trial

Nanobiotix reports promising Phase 2 data for JNJ-1900 (NBTXR3) in inoperable lung cancer, achieving 85.7% overall response rate versus standard care's <5% complete response rate.
JNJNBTXPhase 2 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Nanobiotix

Nanobiotix's Nanoprimer Tech Boosts DNA Immunotherapy Delivery, Cuts Liver Toxicity

Nanobiotix reports preclinical data showing nanoprimer technology improves DNA immunotherapy circulation while reducing hepatic toxicity in mouse models.
NBTXcancer treatmentimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Nanobiotix Communications Department

Nanobiotix's Nanoprimer Shows Promise in Reducing LNP Toxicity, Boosting Drug Delivery

Nanobiotix presented preclinical data showing its Nanoprimer platform reduces liver toxicity and improves bioavailability of LNP-delivered DNA immunotherapies in mouse models.
NBTXNanotechnologybioavailability
BenzingaBenzinga··Vandana Singh

Nanobiotix Shoots Down J&J Acquisition Rumors, Stock Soars on Clarity

Nanobiotix denies J&J acquisition rumors, shares rise 6.17%. Stock up 774.83% annually; reaffirms focus on advancing cancer pipeline, NBTXR3 partnership.
JNJNBTXcancer treatmentbiotechnology
BenzingaBenzinga··Benzinga

NBTX Denies Acquisition Speculation, Refutes Media Claims

Nanobiotix denies acquisition speculation, stating no acquisition intent or assessment underway. Company cites factual inaccuracies in media reports.
NBTXbiotechnologyoncology